Oral Presentation CD1-MR1 2024

Optimizing adoptive immunotherapy of leukemia with CD1c-redirected T cells (#82)

Michela Consonni 1 , Oriane Cazergue 1 , Claudio Garavaglia 1 , Alessandra Mancino 1 , Elise Ramia 1 , Maria Themeli 2 , Sarah Tettamanti 3 , Paolo Dellabona 1 , Giulia Casorati 1
  1. Division of Immunology, Transplantation, and Infectious Diseases; Experimental Immunology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
  2. Department of Hematology, Amsterdam UMC, Location VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands
  3. Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
Publish consent withheld
  1. 1. Lepore M, de Lalla C, Gundimeda SR, Gsellinger H, Consonni M, Garavaglia C, et al. A novel self-lipid antigen targets human T cells against CD1c(+) leukemias. J Exp Med 2014;211:1363-77
  2. 2. Consonni M, Garavaglia C, Grilli A, de Lalla C, Mancino A, Mori L, et al. Human T cells engineered with a leukemia lipid-specific TCR enables donor-unrestricted recognition of CD1c-expressing leukemia. Nat Commun 2021;12:4844
  3. 3. Kuball J, Hauptrock B, Malina V, Antunes E, Voss RH, Wolfl M, et al. Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain. J Exp Med 2009;206:463-75
  4. 4. Ahmadi M, King JW, Xue SA, Voisine C, Holler A, Wright GP, et al. CD3 limits the efficacy of TCR gene therapy in vivo. Blood 2011;118:3528-37
  5. 5. Perriello VM, Rotiroti MC, Pisani I, Galimberti S, Alberti G, Pianigiani G, et al. IL3-zetakine combined with a CD33 costimulatory receptor as a Dual CAR approach for safer and selective targeting of AML. Blood Adv 2022
  6. 6. Katsarou A, Sjostrand M, Naik J, Mansilla-Soto J, Kefala D, Kladis G, et al. Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. Sci Transl Med 2021;13:eabh1962